Comparative Avian Antigen in Bovine Tuberculosis Eradication Protocols

In bovine tuberculosis eradication, the avian-derived antigen functions not as a direct confirmatory endpoint but as a differential comparator in the comparative cervical intradermal test prescribed by 64/432/EEC Annex B and WOAH Terrestrial Manual Chapter 3.4.6. Avian PPD-A is injected at a separate site from bovine PPD-B, and the skin-fold increase at 72 ± 4 h is interpreted as the bovine response minus the avian response. The formulation addition ratio for the ready-to-use injectable solution is a final potency of 25,000 IU/mL, achieved by diluting the API concentrate in phosphate-buffered saline at pH 7.2–7.4 with 0.5% w/v phenol as antimicrobial preservative; the standard intradermal dose of 0.1 mL therefore delivers 2,500 IU per site. Downstream production for this finished product typically begins with 10 kDa tangential flow filtration to remove residual medium components and trichloroacetic acid from the PPD-A bulk, followed by terminal sterile filtration through a 0.22 µm PVDF membrane and aseptic filling into Type I glass vials of 10 mL, 20 mL, or 50 mL. On production-scale TFF systems, shear-induced aggregation is observed when transmembrane pressure exceeds 1.0 bar, producing turbidity above 10 NTU and increasing the risk of false-positive induration at the avian injection site. Vial closure integrity is tested by methylene blue dye ingress under 0.6 bar vacuum. The terminal finished product types for this scenario are limited to ready-to-use injectable solutions and, where market authorisations require, lyophilized powder for reconstitution immediately before intradermal use; tablet, capsule, and feed premix presentations are not supported by the current veterinary pharmacopoeial monographs because the diagnostic action depends on local intradermal antigen deposition rather than systemic absorption. The operational boundary for handling is that repeated freeze-thaw of the liquid bulk must be avoided because protein aggregation increases with each thaw cycle and changes the potency-to-protein ratio used for release. Avian PPD-A liquid is also incompatible with residual chloride levels above isotonic equivalence when vials are stored in unprotected cold-chain packaging, because osmotic shifts during transport promote precipitation on the stopper surface.

Pre-movement certification of layer and breeder birds in national avian tuberculosis control programmes uses the single intradermal wattle test rather than the comparative cervical method applied in cattle. The working formulation for this test is prepared to a final potency of 20,000–25,000 IU/mL in phosphate-buffered saline with 0.5% w/v phenol, the same preservative level used in mammalian tuberculin solutions. Production filling for poultry diagnostic programmes is frequently adjusted to 10 mL multidose vials because flock-level testing involves high through-put and repeated syringe draws under field conditions; each bird receives 0.1 mL by intradermal injection into the wattle, and the injection site is read at 48 ± 4 h with a digital caliper. Terminal finished product types include ready-to-use injectable solutions and lyophilized vials for export markets where cold-chain length exceeds 72 h. The downstream manufacturing process for this format mirrors the mammalian injectable — sterile dilution of the PPD-A concentrate, addition of preservative, terminal filtration through 0.22 µm membrane, and aseptic filling — but the critical control point shifts toward fill-volume precision because a ±10% deviation in delivered volume alters the diagnostic dose at the wattle site. Published data for wattle versus wing-web administration is limited; manufacturers therefore validate injection-site influence on repeated flock screening under their own quality system before filing for national poultry health programme tenders. The applicable standard is the WOAH Terrestrial Manual chapter on avian tuberculosis, supplemented by Ph. Eur. sterility testing according to 2.6.1 and bacterial endotoxin testing according to 2.6.14 when the product is supplied as a reconstitution kit.

What Controls Potency Drift in Lyophilized PPD-A Reference Reagents?

Potency drift in lyophilized avian tuberculin reference reagents is governed less by the primary drying phase than by excipient crystallization dynamics during storage and by residual moisture ingress after stopper closure. The reference reagent format requires the PPD-A API concentrate to be diluted before freeze-drying to a protein equivalent of 1.0–3.0 mg/mL with a cryoprotectant-to-antigen ratio of 2–5% w/v mannitol or 2% w/v lactose, depending on the collapse temperature determined by freeze-drying microscopy; the final reconstituted potency is adjusted to 25,000 IU/mL against the WOAH reference preparation. Downstream production for this format uses 3 mL Type I glass vials filled semi-automatically under grade A conditions, frozen on pre-cooled shelves to -40 °C, and lyophilized with a chamber pressure of 50–100 mTorr and a shelf ramp from -40 °C to +25 °C over 36 h. The critical process parameter is residual moisture, which must remain below 2.0% w/w; stopper closure under partial vacuum or dry nitrogen is required to prevent moisture-induced cake shrinkage. Published data for avian PPD-specific degradation kinetics is limited, so manufacturers apply VICH GL3 stability protocols to establish lot-specific expiry rather than relying on compendial fixed dating. Terminal finished product types include lyophilized reference reagents, kit positive controls for avian differential panels, and working standards for QC laboratories that release injection-grade PPD-A. Compliance anchors for this downstream track are ISO 17034:2016 for reference material producers and ISO 13485:2016 for in-vitro diagnostic reagent manufacturing, with potency assignment certified through the guinea pig intradermal model referenced in the Ph. Eur. tuberculin monograph.

Heparinised whole blood from cattle that have responded to the single cervical intradermal test can be re-evaluated with avian PPD-A in the interferon-gamma release assay to subtract environmental mycobacterial sensitisation. In this in-vitro diagnostic format, the PPD-A working solution is added to whole blood to a final concentration of 10–20 µg/mL, and the culture is incubated at 37 °C for 16–24 h; the avian-stimulated IFN-γ optical density is then subtracted from the bovine-stimulated value to correct for cross-reactivity with non-tuberculous mycobacteria. The manufacturing process for this grade differs from the injectable product because the addition of 0.5% w/v phenol is not permitted; in-vitro-grade PPD-A is therefore formulated without preservative, sterile-filtered through 0.22 µm membrane, and aseptically filled into 2 mL single-use glass vials or frozen bulk aliquots stored at 2–8 °C for liquid formats. Endotoxin is controlled to <0.5 EU/mL by Ph. Eur. 2.6.14, and the absence of cytotoxic preservatives is verified by lymphocyte viability testing before release. Terminal finished product types include in-vitro diagnostic antigen solutions for IFN-γ EIA kits, single-use frozen aliquots for automated liquid handling platforms, and kit-matched avian antigen controls. The applicable laboratory standard for the end user is ISO 17025:2017; the assay itself falls under the diagnostic pathway described in WOAH Terrestrial Manual Chapter 3.4.6. The operational boundary is that injection-grade PPD-A containing phenol must not be substituted for the in-vitro grade, because the preservative suppresses IFN-γ secretion in cultured lymphocytes and produces false-negative avian subtraction. Repeated opening of a single-use vial under routine laboratory conditions is not recommended beyond 8 h because preservative-free antigen is susceptible to airborne bacterial contamination.

When Multi-Species Zoo Surveillance Requires Non-Ruminant Antigen Sourcing

When a zoological collection maintains both Galliformes and exotic ungulates, the same PPD-A liquid bulk is typically split into multiple filling configurations because bird wattle testing requires very small dose volumes while larger mammals may require species-validated injection depths. The final potency remains 25,000 IU/mL, with a standard avian dose of 0.1 mL intradermally; published data for non-avian dose volumes is limited, so zoological programmes validate the injection volume by pre-trial skin-fold measurement in the target species. Compliance for this downstream use is anchored to the WOAH Terrestrial Manual plus national zoo disease-surveillance permits, and import/export certification frequently requires individual animal identification and reading at 48 h and 72 h post-injection. Formulation addition ratio is not materially altered from the cattle-test solution, but the fill presentation is changed to 1 mL single-dose vials to reduce preservative exposure in small-bodied birds and to prevent multiple-use stopper contamination in field settings with high humidity. Production is performed by aseptic split-filling from a single batch into 1 mL vials with fill volume accuracy of ±5%; secondary packaging includes calibrated temperature loggers because zoo field transport often exceeds 24 h under non-refrigerated conditions. Terminal product types for this segment are single-dose injectable solutions and, for remote collections without consistent cold-chain access, lyophilized vials reconstituted with sterile saline immediately before injection. The operational limitation is that PPD-A is not formulated into oral or feed-based presentations for wildlife; intradermal deposition is the only validated route described in the current WOAH diagnostic chapter. Incompatibility with silicone-coated syringes can occur during prolonged hold times, as silicone oil droplets promote particulate formation in protein-antigen solutions, particularly when the vial has been exposed to repeated temperature cycling.

Lot-to-lot normalisation of avian PPD API against the WOAH reference preparation is a release prerequisite before any of the above downstream formats are filled. The working reference aliquot is produced by diluting the API concentrate to a target protein concentration in phosphate buffer, then assigning potency in sensitised guinea pigs using intradermal challenge; release potency must fall within 80–120% of the stated label claim in the Ph. Eur. tuberculin monograph potency assay. The production process for this QC application includes sterile filtration of the diluted reference solution, filling into 0.5 mL screw-cap cryovials, and storage at -70 °C for long-term stability; lyophilized working standards are also produced when the receiving laboratory cannot maintain ultra-low-temperature storage. Measurement equipment includes a digital caliper with 0.01 mm resolution for skin reactions and a calibrated balance with 0.01 mg readability for gravimetric fill checks. Terminal finished product types for this downstream track are certified working reference aliquots, lyophilized comparative standards, and QC release kits used by vaccine and diagnostic manufacturers to verify batch-to-batch consistency. Compliance anchors are ISO 17034:2016 for reference material producers and the WOAH Terrestrial Manual for potency assignment, with sterility confirmed by Ph. Eur. 2.6.1 and endotoxin by Ph. Eur. 2.6.14. The operational boundary is that frozen working references must be aliquoted into single-use volumes before freezing; repeated freeze-thaw of a bulk reference pool produces potency shifts outside the 80–120% release window and invalidates subsequent batch comparisons.